Proprietary AI analyst is now available
- Public Comps
- Accuray
Accuray Valuation Multiples
Discover revenue and EBITDA valuation multiples for Accuray and similar public comparables like Mauna Kea Technologies, Luna Innovations, RenovoRx, Mentice and more.
Accuray Overview
About Accuray
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
Founded
1990
HQ

Employees
990
Website
Financials (LTM)
EV
$184M
Valuation Multiples
Start free trialAccuray Financials
Accuray reported last 12-month revenue of $410M and EBITDA of $2M.
In the same LTM period, Accuray generated $106M in gross profit, $2M in EBITDA, and had net loss of ($38M).
Revenue (LTM)
Accuray P&L
In the most recent fiscal year, Accuray reported revenue of $459M and EBITDA of $28M.
Accuray is unprofitable as of last fiscal year, with gross margin of 32%, EBITDA margin of 6%, and net margin of (0%).
Financial data powered by Morningstar, Inc.
Accuray Stock Performance
Accuray has current market cap of $39M, and enterprise value of $184M.
Market Cap Evolution
Accuray's stock price is $0.33.
Accuray share price decreased by 14.4% in the last 30 days, and by 76.0% in the last year.
Accuray has an EPS (earnings per share) of $-0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $184M | $39M | -1.3% | -14.4% | -15.2% | -76.0% | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAccuray Valuation Multiples
Accuray trades at 0.4x EV/Revenue multiple, and 75.8x EV/EBITDA.
EV / Revenue (LTM)
Accuray Financial Valuation Multiples
As of June 11, 2026, Accuray has market cap of $39M and EV of $184M.
Accuray has a P/E ratio of (1.0x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Accuray Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Accuray Margins & Growth Rates
Accuray decreased revenue by 11% and EBITDA by 96% in the last fiscal year.
In the most recent fiscal year, Accuray reported gross margin of 32%, EBITDA margin of 6%, and net margin of (0%).
Accuray Margins
Accuray Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Accuray Operational KPIs
Accuray's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.1M for the same period.
Accuray's Rule of 40 is (3%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Accuray's Rule of X is (11%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Accuray Competitors
Accuray competitors include Mauna Kea Technologies, Luna Innovations, RenovoRx, Mentice, Abingdon Health, Q-linea, Optomed, Baird Medical Investment, Diagnostic Medical Systems and Nutriband.
Most Accuray public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 5.0x | 5.1x | 3.2x | (13.2x) | |||
| - | - | - | - | |||
| 23.3x | 12.8x | (2.1x) | - | |||
| 1.2x | 1.1x | 77.1x | 26.7x | |||
| 3.2x | 2.3x | (10.7x) | (25.3x) | |||
| 12.5x | - | (0.9x) | - | |||
| 1.6x | 1.5x | (7.6x) | (10.9x) | |||
| 2.7x | - | (2.5x) | - | |||
This data is available for Pro users. Sign up to see all Accuray competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Accuray
| When was Accuray founded? | Accuray was founded in 1990. |
| Where is Accuray headquartered? | Accuray is headquartered in United States. |
| How many employees does Accuray have? | As of today, Accuray has over 990 employees. |
| Who is the CEO of Accuray? | Accuray's CEO is Stephen R. LaNeve. |
| Is Accuray publicly listed? | Yes, Accuray is a public company listed on Nasdaq. |
| What is the stock symbol of Accuray? | Accuray trades under ARAY ticker. |
| When did Accuray go public? | Accuray went public in 2007. |
| Who are competitors of Accuray? | Accuray main competitors include Mauna Kea Technologies, Luna Innovations, RenovoRx, Mentice, Abingdon Health, Q-linea, Optomed, Baird Medical Investment, Diagnostic Medical Systems, Nutriband. |
| What is the current market cap of Accuray? | Accuray's current market cap is $39M. |
| What is the current revenue of Accuray? | Accuray's last 12 months revenue is $410M. |
| What is the current revenue growth of Accuray? | Accuray revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Accuray? | Current revenue multiple of Accuray is 0.4x. |
| What is the current EBITDA of Accuray? | Accuray's last 12 months EBITDA is $2M. |
| What is Accuray's EBITDA margin? | Accuray's last 12 months EBITDA margin is 1%. |
| What is the current EV/EBITDA multiple of Accuray? | Current EBITDA multiple of Accuray is 75.8x. |
| How many companies Accuray has acquired to date? | Accuray hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Accuray has invested to date? | Accuray hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Accuray
Lists including Accuray
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.